PE20120538A1 - Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico - Google Patents

Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico

Info

Publication number
PE20120538A1
PE20120538A1 PE2011002156A PE2011002156A PE20120538A1 PE 20120538 A1 PE20120538 A1 PE 20120538A1 PE 2011002156 A PE2011002156 A PE 2011002156A PE 2011002156 A PE2011002156 A PE 2011002156A PE 20120538 A1 PE20120538 A1 PE 20120538A1
Authority
PE
Peru
Prior art keywords
methyl
benzazepin
tetrahydro
trifluoromethyl
bis
Prior art date
Application number
PE2011002156A
Other languages
English (en)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20120538A1 publication Critical patent/PE20120538A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A L COMPUESTO ACIDO TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETIL)FENIL]METIL](2-METIL-2H-TETRAZOL-5-IL)AMINO]-2,3,4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL]METIL]-CICLOHEXACARBOXILICO, UN HIDRATO O SAL DEL MISMO. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION, UNA COMPOSICION FARMACEUTICA Y A UN HIDRATO CRISTALINO DE DICHO COMPUESTO QUE PRESENTA UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X OBTENIDO DE UNA FUENTE DE CuKALFA CON LOS SIGUIENTES PICOS: a) 7,5, 9,2, 10,7 Y 15,5 +/- 0,2 EN 2 THETA O b) 7,5, 9,2, 10,7, 13,8, 15,0, 15,5 Y 19,5 +/- 0,2 EN 2 THETA O c) 7,5, 9,2, 10,7, 13,8, 11,3, 15,0, 15,5, 17,7, 19,5 Y 25,1 +/- 0,2 EN 2 THETA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES INCLUYENDO LA DISLIPIDEMIA Y ATEROSCLEROSIS
PE2011002156A 2009-06-30 2010-06-28 Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico PE20120538A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
PE20120538A1 true PE20120538A1 (es) 2012-05-09

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002156A PE20120538A1 (es) 2009-06-30 2010-06-28 Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico

Country Status (37)

Country Link
US (2) US8299060B2 (es)
EP (1) EP2448933B1 (es)
JP (1) JP5689875B2 (es)
KR (1) KR101404893B1 (es)
CN (1) CN102639528B (es)
AR (1) AR077208A1 (es)
AU (1) AU2010266537B2 (es)
BR (1) BRPI1011931A2 (es)
CA (1) CA2764425C (es)
CL (1) CL2011003263A1 (es)
CO (1) CO6480934A2 (es)
CR (1) CR20110669A (es)
DK (1) DK2448933T3 (es)
DO (1) DOP2011000405A (es)
EA (1) EA020600B1 (es)
EC (1) ECSP11011551A (es)
ES (1) ES2435293T3 (es)
GT (1) GT201100321A (es)
HR (1) HRP20130950T1 (es)
IL (1) IL216655A (es)
JO (1) JO2867B1 (es)
MA (1) MA33385B1 (es)
ME (1) ME01606B (es)
MX (1) MX2011014024A (es)
MY (1) MY157121A (es)
NZ (1) NZ596820A (es)
PE (1) PE20120538A1 (es)
PL (1) PL2448933T3 (es)
PT (1) PT2448933E (es)
RS (1) RS52988B (es)
SG (1) SG177413A1 (es)
SI (1) SI2448933T1 (es)
TN (1) TN2011000638A1 (es)
TW (1) TWI450896B (es)
UA (1) UA109409C2 (es)
WO (1) WO2011002696A1 (es)
ZA (1) ZA201108707B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
TWI627167B (zh) * 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
MX2015009851A (es) 2013-01-31 2015-10-14 Chong Kun Dang Pharm Corp Compuestos derivados de ciclohexeno sustituidos con biarilos o biarilos heterociclicos como inhibidores de cetp.
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
MX2017000582A (es) 2014-07-30 2017-04-27 Hoffmann La Roche Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (es) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
DK1425270T3 (da) 2001-04-30 2006-07-03 Pfizer Prod Inc Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
EP1556047A4 (en) 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2004078730A2 (en) 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
ATE442358T1 (de) * 2003-10-08 2009-09-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
WO2005097806A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸

Also Published As

Publication number Publication date
PL2448933T3 (pl) 2014-01-31
DK2448933T3 (da) 2013-10-07
AU2010266537B2 (en) 2013-04-18
PT2448933E (pt) 2013-10-29
UA109409C2 (ru) 2015-08-25
MY157121A (en) 2016-05-13
US8299060B2 (en) 2012-10-30
ES2435293T3 (es) 2013-12-18
GT201100321A (es) 2012-11-15
CA2764425C (en) 2015-01-06
CO6480934A2 (es) 2012-07-16
AU2010266537A1 (en) 2012-02-02
JO2867B1 (en) 2015-03-15
CN102639528B (zh) 2014-07-16
US20120058990A1 (en) 2012-03-08
ZA201108707B (en) 2013-05-29
EA020600B1 (ru) 2014-12-30
CA2764425A1 (en) 2011-01-06
HRP20130950T1 (hr) 2013-11-22
EP2448933A1 (en) 2012-05-09
CL2011003263A1 (es) 2012-07-27
CN102639528A (zh) 2012-08-15
ECSP11011551A (es) 2012-01-31
TN2011000638A1 (en) 2013-05-24
DOP2011000405A (es) 2012-01-15
JP2012532106A (ja) 2012-12-13
EP2448933B1 (en) 2013-08-28
TW201113275A (en) 2011-04-16
EA201270099A1 (ru) 2012-05-30
MA33385B1 (fr) 2012-06-01
SG177413A1 (en) 2012-02-28
AR077208A1 (es) 2011-08-10
US8329688B2 (en) 2012-12-11
NZ596820A (en) 2013-07-26
JP5689875B2 (ja) 2015-03-25
KR101404893B1 (ko) 2014-06-20
MX2011014024A (es) 2012-04-20
KR20120027426A (ko) 2012-03-21
ME01606B (me) 2014-09-20
RS52988B (en) 2014-02-28
IL216655A (en) 2015-02-26
CR20110669A (es) 2012-03-16
TWI450896B (zh) 2014-09-01
IL216655A0 (en) 2012-02-29
BRPI1011931A2 (pt) 2016-04-19
US20100331309A1 (en) 2010-12-30
WO2011002696A1 (en) 2011-01-06
SI2448933T1 (sl) 2013-11-29

Similar Documents

Publication Publication Date Title
PE20120538A1 (es) Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico
HRP20171197T1 (hr) Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
CL2013000929A1 (es) Forma cristalina c de la sal sodica del acido (4-(4-(5-(6-trifluoro metil piridin-3-il-amino) piridin-2-il-) fenil)-ciclohexil)-acetico; proceso de preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento de un trastorno asociado con la actividad del dagt.
EA201101210A1 (ru) 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh для лечения легочной функции
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TH115567B (th) ทราสนส์-4-[[(5s)-5-[[[3,5-บิส(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล](2-เมธิล-2h-เททาโซล-5-อิล)อะมิโน]-2,3,4,5-เททราไฮโดร-7,9-ไดเมธิล-1h-1-เบนแซซีพิน-1-อิล]-ไซโคลเฮกเซนคาร์บอกซิลิค แอซิด
EP2517709A4 (en) MEDICAL AND PHARMACEUTICAL USE OF NON-NUCLEOSIDE COMPOUNDS OF 2 ', 2-BIS-THIAZOLE AS INHIBITORS OF HEPATITIS C VIRUS
RS54022B1 (en) COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE
TH98361B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH89286B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH98362B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH90669B (th) เก้าอี้
UA109560C2 (ru) Кристаллические фармацевтически активные формы
IN2013CH00918A (es)
TH89285B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH89284B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH98363B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH89281B (th) ผ้าอ้อมใช้แล้วทิ้ง
TH89283B (th) ผ้าอ้อมใช้แล้วทิ้ง
HN2011003208A (es) Acido trans-4-[[(5s)-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil-ciclohexancarboxilico
TH116289B (th) กระบอกด้าย

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed